• Voyager Therapeutics (VYGR) is trading 5.3% up today at $3.81.
  • The company recently received FDA Investigational New Drug (IND) clearance for VY1706, its gene therapy for Alzheimer's disease, enabling a clinical trial in adults.
  • VY1706 is also set to be featured in a developing topics poster presentation at the Alzheimer's Association International Conference (AAIC) from July 12-15, 2026.
  • Dosing for the VY1706 clinical trial is expected to begin in the second half of 2026.